- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01581281
The Childhood and Adolescent Migraine Prevention Study (CHAMP)
Amitriptyline and Topiramate in the Prevention of Childhood Migraine
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Phoenix Children's Medical Group
-
-
California
-
San Francisco, California, United States, 94115
- University of California-San Francisco Headache Center
-
Stanford, California, United States, 94305
- Stanford Hospital and Clinics
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
Colorado Springs, Colorado, United States, 80907
- Colorado Springs Neurological Associates
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
West Palm Beach, Florida, United States, 33407
- Premiere Research Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Atlanta Headache Specialists
-
-
Indiana
-
Indianapolis, Indiana, United States, 46237
- Josephson Wallack Munshower Neurology Research
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Children's Mercy Hospital
-
-
Kentucky
-
Louisville, Kentucky, United States, 40292
- University of Louisville Health Sciences Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland School of Medicine
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02453
- Children's Hospital of Boston
-
Worcester, Massachusetts, United States, 01605
- New England Regional Headache Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63104
- Saint Louis University
-
-
Nevada
-
Reno, Nevada, United States, 89502
- University of Nevada
-
-
New York
-
Amherst, New York, United States, 14226
- Dent Neurological Institute
-
Mineola, New York, United States, 11501
- Winthrop University Hospital
-
New York, New York, United States, 10019
- The Headache Institute at Roosevelt Hospital
-
Schenectady, New York, United States, 12308
- Schenectady Neurological Constultants, PC
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, United States, 44195
- The Children's Hospital, Cleveland Clinic
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma Health Sciences
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15236
- Preferred Clinical Research
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- LeBonheur Children's Hospital
-
-
Texas
-
Dallas, Texas, United States, 75230
- Dallas Pediatric Neurology Associates
-
Temple, Texas, United States, 76508
- Scott and White Healthcare
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Primary Children's Medical Center
-
-
Virginia
-
Norfolk, Virginia, United States, 23510
- Eastern Virginia Medical School
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Wisconsin
-
Marshfield, Wisconsin, United States, 54449
- Marshfield Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Migraine with or without aura (International Classification of Headache Disorders, 2nd Edition (ICHD-II) or chronic migraine (ICHD-II revised)
- Migraine frequency based upon prospective headache diary of 28 days must be ≥ 4. Migraine frequency defined as any migraine during one day in the 28 day baseline period (1)
- PedMIDAS Disability Score > 10, indicating at least mild disruption in daily activities and < 140, indicating extreme disability that may require more comprehensive, multi-component therapy
Females or males 8-17 years, inclusive
- Migraine frequency is defined as the period from the onset to the stop time of painful migraine symptoms not to exceed 24 hours with the clock starting at midnight. If painful symptoms last longer than 24 hours, this is considered a new and distinct migraine headache. If painful symptoms recur within 24 hours of initial onset, this is considered part of the initial migraine episode and would be counted as one migraine.
Exclusion Criteria:
- Continuous migraine defined as an unrelenting headache for a 28 day period
- Weight less than 30 kg or greater than 120 kg
- Unwilling to avoid taking non-specific acute medication such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications such as triptans more than 6 times per month
- Currently taking other prophylactic anti-migraine medication within a period equivalent to 2 weeks of that medication before entering the screening phase, or the use of Botulinum toxin (Botox®) within 3 months of entering the screening phase
- Subjects who have previously failed an adequate trial of AMI or TPM for prophylaxis of at least 3 months duration at doses recommended for migraine relief because of lack of efficacy or adverse events(2)
- Current use of disallowed medications/products: opioids, antipsychotics, antimanics, barbiturates, benzodiazepines, muscle relaxants, sedatives, tramadol, nutraceuticals, SSRIs, or SSNRIs
- Known history of allergic reaction or anaphylaxis to AMI or TPM
- Abnormal findings on ECG at baseline, particularly lengthening of the QT interval greater than or equal to 450 msec
- Subject is pregnant or has a positive pregnancy test
- Subject is sexually active and not using a medically acceptable form of contraception
- Diagnosis of epilepsy or other neurological diseases
- History of kidney stones
- Inability to swallow pills after using behavioral techniques if indicated between screening visit and baseline visit (3)
- Present psychiatric disease as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) (e.g. psychosis, bipolar disorder, major depression, generalized anxiety disorder), alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) that, in the opinion of the site investigator, would interfere with adherence to study requirements or safe participation in the trial
Any and all other diagnoses or conditions which in the opinion of the site investigator, that would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the study subject
(2)"Previously failed an adequate trial of AMI or TPM" is defined as: dosage of 1mg/kg/day of AMI or 2 mg/kg/day of TPM; trial of at least 3 months duration; efficacy of having at least a 50% decrease in migraine frequency in response to drug therapy; or unable to tolerate taking the medication due to treatment-related side effects.
(3)Subjects who cannot swallow pills at the time of the screening visit will be given a training session using behavioral techniques. Upon return for baseline visit, if the subject continues to be unable to swallow pills, the subject will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Amitriptyline
Drug to be administered twice daily.
|
Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose.
The morning dose is a placebo pill.
Dosing of amitriptyline will be weight-based.
|
ACTIVE_COMPARATOR: Topiramate
Drug to be administered twice daily.
|
Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose.
Dosing of topiramate will be weight-based.
|
PLACEBO_COMPARATOR: Placebo
To be administered twice daily.
|
Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number (Percentage) of Participants Reporting a ≥ 50% Reduction in Headache Days
Time Frame: 4 week baseline period and last 4 weeks of the 24-week trial
|
The primary endpoint was a ≥ 50% reduction in headache frequency from the 28 days (4 weeks) baseline period prior to randomization to the last 28 days (4 weeks) of the trial. Headache frequency was defined as the number of days with headache for a given four week 28 day (4 week) period. A headache day was defined as any day during which any headache occurs within a 24 hour period, starting and ending at midnight. For each participant, the primary endpoint involved a determination of whether a 50% or greater reduction in headache frequency was observed during the last 4 weeks of active treatment as compared with the headache frequency during the 4-week baseline period. Results were compared across the three treatment groups. |
4 week baseline period and last 4 weeks of the 24-week trial
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Absolute Headache Disability Score on PedMIDAS
Time Frame: baseline and 24 week endpoint
|
The PedMIDAS scale which evaluated the impact of headaches in school, home, play, and social activities, is comprised of six items that pertain to days missed in various activities over the past 90 days. Questions were answered by the youth in consultation with their parents and reviewed by study staff. The PedMIDAS scale was administered at baseline (covering the three months prior to enrollment) and at the 24-week endpoint visit (the end of the maintenance period, covering three months of enrollment). A total PedMIDAS score (sum of items 1-6) was used in this trial. Scores range from 0-240; with a score of 0-10 indicating no disability, 11-30 mild disability, 31-50 moderate disability, and more than 50 severe disability in daily activities. The main outcome measure for this comparison will be the difference in the baseline and endpoint (24 week) PedMIDAS total scores for:
|
baseline and 24 week endpoint
|
Change in Number of Headache Days
Time Frame: 4 week baseline period and last 4 weeks of the 24-week trial
|
This outcomes measure examines whether the rate of absolute number of headache days, per 28 day period, differs between treatment groups over time. This was assessed longitudinally based on the actual number of headache days from the 28 days prior to randomization to the last 28 days of this 24 week trial. The change in absolute headache days was compared between:
|
4 week baseline period and last 4 weeks of the 24-week trial
|
Tolerability, as Indicated by the Number (Percentage) of Participants That Completed the 24-week Treatment Phase
Time Frame: 24 weeks
|
To assess tolerability, the percentage of subjects who complete the entire 24-week treatment period will be estimated in each of the three groups.
|
24 weeks
|
Occurrence of Treatment Emergent Serious Adverse Events
Time Frame: 24 weeks of the trial
|
To determine if amitriptyline or topiramate differ from placebo on the occurrence of treatment emergent serious adverse events.
|
24 weeks of the trial
|
Collaborators and Investigators
Investigators
- Principal Investigator: Scott W. Powers, PhD, Children's Hospital Medical Center, Cincinnati
- Principal Investigator: Andrew D. Hershey, MD, PhD, Children's Hospital Medical Center, Cincinnati
- Principal Investigator: Christopher S. Coffey, PhD, University of Iowa
Publications and helpful links
General Publications
- Reidy BL, Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Peugh J, Kabbouche MA, Kacperski J, Hershey AD; CHAMP Investigators. Multimodal Assessment of Medication Adherence Among Youth With Migraine: An Ancillary Study of the CHAMP Trial. J Pediatr Psychol. 2022 Apr 8;47(4):376-387. doi: 10.1093/jpepsy/jsab123.
- Reidy BL, Peugh J, Hershey AD, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Kabbouche MA, Kacperski J, Powers SW. Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial. Cephalalgia. 2022 Jan;42(1):44-52. doi: 10.1177/03331024211033551. Epub 2021 Aug 17.
- Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD; CHAMP Investigators. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. N Engl J Med. 2017 Jan 12;376(2):115-124. doi: 10.1056/NEJMoa1610384. Epub 2016 Oct 27.
- Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL; CHAMP Study Group. Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013 May;53(5):799-816. doi: 10.1111/head.12105. Epub 2013 Apr 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Headache
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Anticonvulsants
- Antidepressive Agents, Tricyclic
- Adrenergic Uptake Inhibitors
- Amitriptyline
- Topiramate
Other Study ID Numbers
- CIN-001
- 1U01NS076788-01 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Amitriptyline
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Peripheral Nervous System DiseaseUnited States
-
First Affiliated Hospital of Zhejiang UniversityHunan DongtingPharm.Co.LtdCompleted
-
University of Missouri, Kansas CityRecruitingAutism Spectrum Disorder | Repetitive Compulsive BehaviorUnited States
-
UMC UtrechtUtrecht UniversityTerminatedChronic Neuropathic PainNetherlands
-
AlgoTherapeutixRecruiting
-
Gil YosipovitchTerminated
-
University Hospital TuebingenCompletedCystic Fibrosis | Infection | Pseudomonas AeruginosaGermany
-
CAMC Health SystemNational Institutes of Health (NIH); National Institute of General Medical... and other collaboratorsUnknownGallbladder DyskinesiaUnited States
-
Tufts Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Mayo ClinicRecruitingInterstitial Lung DiseaseUnited States